Q-omics provides the consensus-scored MTATP6P15 profile across patient tissues and cancer cell-line models. MTATP6P15 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, MTATP6P15 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, MTATP6P15 RNA expression shows 7,986 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight TGCT, HNSC, and PDAC as cancer lineages where MTATP6P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTATP6P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTATP6P15 survival associations across molecular data types. MTATP6P15 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTATP6P15 RNA expression–survival associations across cancer types. High MTATP6P15 expression shows unfavorable associations in TGCT, LIHC, STAD and PAAD, but favorable associations in LUAD and HNSC. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for MTATP6P15 RNA expression.
This table summarizes MTATP6P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTATP6P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTATP6P15 shows lower tumor expression in UCEC and higher tumor expression in HNSC and BRCA. The HNSC box plot shows higher MTATP6P15 RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .008).
This table shows molecular features associated with MTATP6P15 in patient tissues and cancer cell lines. In patient samples, MTATP6P15 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
